CDC-RFA-IP21-2102: Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - NCIRD notices from 2021.
Centers for Disease Control - NCIRD offered grants to the applicants described in the notice. It expected to make about 6 awards worth $41.0 million in total. Applications closed on June 21, 2021.
From the official notice on Grants.gov, last changed April 22, 2021. Checked November 7, 2026.
- Total funding$41.0 million
- Expected awards6
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 21, 2021 |
|---|---|
| Deadline | June 21, 2021 |
| Archived by Grants.gov | July 22, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Regional Offices of the World Health Organization Regional Office for Africa – AFR, Brazzaville, Congo; Regional Office for the Americas – PAHO, Washington, D.C.; Regional Office for South-East Asia – SEAR, New Delhi, India; Regional Office for Europe – EUR, Copenhagen, Denmark; Regional Office for the Eastern Mediterranean – EMR, Cairo, Egypt; and Regional Office for the Western Pacific – WPR, Manila, Philippines).
Is this a realistic fit?
- Most of the program's money (49% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) will support the Regional Offices of the World Health Organization (WHO) to implement a coordinated plan to assist national governments and regional authorities to improve surveillance for influenza by enhancing capacity for laboratory and epidemiologic surveillance of seasonal and pandemic influenza; to assist in implementation of simple methods to determine burden of influenza disease in countries and regionally using surveillance data and other routinely collected information; to detect and respond to outbreaks of novel influenza viruses with pandemic potential, such as highly pathogenic avian influenza, swine viruses or other respiratory pathogens with similar pandemic potential; and, to assist countries to conduct activities that inform policies on introduction and increased use of influenza vaccines. Projects considered for this NOFO should build upon existing public health infrastructure focusing on country priorities, strengthen regional and national partnerships, public health capacity, leadership, and strategic collaboration and integrated health programming throughout the Region. Only one application per WHO Regional Office may be submitted. Activities identified should be complementary and not duplicative to the activities targeted through WHO’s Pandemic Influenza Preparedness Framework (PIP) or any other similar projects occurring within a region.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-IP21-2102 still open?
No. It closed on June 21, 2021. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization?
Centers for Disease Control - NCIRD accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization?
Closed June 21, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $41.0 million in total across about 6 awards.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before?
The largest recipients over five fiscal years were African Field Epidemiology Network LTD, The Task Force for Global Health, Inc., World Health Organization, Somalia. The program made 306 awards worth $1.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)